CD8A and neoplasm: CD8+ cytotoxic T cells with an αβ T cell receptor are the main targets for immune checkpoint inhibition as these immune cells recognize tumor neo-antigens presented on MHC class I. Therefore, in CRCs, checkpoint inhibition is restricted to tumors with a high mutational burden.